Studies have demonstrated that silencing UCA1 in NSCLC cell lines increases their sensitivity to EGFR-TKIs, while the overexpression of UCA1 leads to a reduced efficacy of these drugs [155]. Here, UCA1 is linked to non-small cell lung carcinoma.